US Stock MarketDetailed Quotes
IRWD Ironwood Pharmaceuticals
- 8.100
- -0.210-2.53%
Close Apr 24 16:00 ET
1.27BMarket Cap-1255P/E (TTM)
8.355High8.090Low1.85MVolume8.240Open8.310Pre Close15.11MTurnover1.35%Turnover RatioLossP/E (Static)156.53MShares15.70052wk High-3.66P/B1.11BFloat Cap7.53052wk Low--Dividend TTM137.03MShs Float21.200Historical High--Div YieldTTM3.19%Amplitude7.350Historical Low8.150Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Ironwood Pharmaceuticals Stock Forum
ColumnsIronwood Pharma Shares Tank 40% as Drug Trial Misses Secondary Goal
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...
Biotech Stock Catalyst Watchlist
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...
Ph 3 readouts in Q1 2024...
$Regenxbio(RGNX.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Vertex Pharmaceuticals(VRTX.US)$ Phase 3
$KalVista Pharmaceuticals(KALV.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$Applied Therapeutics(APLT.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3...
Ph2 readouts in Q1 2024...
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
Upcoming Ph 2 readouts in Q1 2024…
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
ColumnsWeekly FDA Drug Pipeline Calendar (Feb 13 - Feb 17)
Next week big pharma companies such as $Biogen(BIIB.US)$ , $Sage Therapeutics(SAGE.US)$ , and$Ironwood Pharmaceuticals(IRWD.US)$ will release their quarterly earnings report.
BIGGEST MOVERS FROM THIS WEEK
$Hillstream BioPharma(HILS.US)$ shares continued to trade up this week after it announced initial results from a study...
ColumnsToday's Pre-Market Stock Movers: DWAC, BBBY, ILMN, DBX and More
In reaction to earnings/guidance:
• $United Microelectronics(UMC.US)$ +0.8% (August revs)
Other news:
• $ChannelAdvisor(ECOM.US)$ +54.4% (to be acquired for $23.10 per share)
• $IVERIC bio(ISEE.US)$ +42.3% (topline data from Zimura GATHER2 phase 3 clinical trialingeographic atrophy)
• $Monte Rosa Therapeutics(GLUE.US)$ +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)
• $IDEAYA Biosciences(IDYA.US)$ +4.9% (re...
No comment yet